Xiidra vs. Restasis: Complete Comparison

One of the most important practical differences between these two medications is how quickly patients may begin to notice improvement. In clinical trials, some individuals using Xiidra reported measurable improvement in dry eye symptoms as early as two weeks, with significant benefits observed by week six to twelve. This relatively fast onset makes Xiidra an appealing choice for patients who are looking for noticeable comfort sooner. Identifying contributing factors such as medications, systemic health conditions, hormonal changes, and environmental exposures is an important part of the evaluation process, because addressing these influences alongside direct ocular surface treatment often leads to more sustained improvement.

Restasis works more gradually. Because cyclosporine suppresses the immune-driven inflammation that decreases tear production, the eye needs time to recover its natural tear-producing ability. Most patients begin to notice improved tear volume and comfort within three to six months of consistent twice-daily use. Each patient receives a customized management plan that may evolve over time as symptoms improve or new contributing factors emerge, ensuring that the approach remains aligned with your current needs and goals.

Neither medication provides overnight results. The inflammatory process underlying dry eye disease develops over months or years, and reversing it takes time regardless of which drop you use. Our dry eye specialists will schedule follow-up visits to track your progress. Using artificial tears alongside your prescription drops may also help bridge the gap while waiting for full therapeutic effect. The relationship between eyelid health and tear film stability is well established in the clinical literature, and addressing lid margin disease is often a necessary foundation for effective dry eye treatment.

Both Xiidra and Restasis have demonstrated effectiveness in clinical trials. Xiidra showed significant symptom improvement by week 12, while Restasis demonstrated a meaningful increase in tear production at six months. A recent comparative study found that lifitegrast may offer faster symptomatic relief, while cyclosporine remains a strong option for sustained long-term management. The better choice depends on your specific symptoms and how your eyes respond.

Neither Xiidra nor Restasis directly treats gland blockages. However, both medications can reduce the surrounding inflammation that contributes to gland damage. Our dry eye specialists often combine prescription anti-inflammatory drops with in-office treatments like thermal pulsation therapy to address meibomian gland dysfunction more comprehensively.

Restasis has a significant cost advantage because a generic version of cyclosporine 0.05% is now available. Generic cyclosporine can cost substantially less than brand-name options. Xiidra does not yet have a generic equivalent, making its retail price higher. Both manufacturers offer savings programs for eligible patients with commercial insurance.

Because Xiidra and Restasis target different parts of the inflammatory process, some eye care providers do prescribe them together for patients with severe or treatment-resistant dry eye. This combination approach aims to address inflammation through two complementary pathways simultaneously. However, using two prescription drops increases the daily drop burden and cost, so this strategy is typically reserved for patients who have not achieved adequate relief with a single agent.

The best starting point is a thorough dry eye evaluation that includes measurement of your tear production, tear film break-up time, meibomian gland imaging, and ocular surface staining. Patients who need faster relief and can manage the higher cost may lean toward Xiidra, while those looking for a well-established, more affordable long-term therapy may prefer Restasis or its generic. Your overall health history, other medications, and personal preferences all play a role.